Search clinical trials for: Liposomal paclitaxel

Total 5949 results

AstraZeneca

Terminated

Efficacy and Safety of AZD4547 Versus Paclitaxel in Patients With Advanced Gastric or Gastro-oesophageal Cancer (SHINE)

Gastric Cancer | Gastro-oesophageal Junction Cancer

Bulgaria, Czech Republic, Italy, Korea, Republic of, Spain, United Kingdom, Hungary, Romania, Ukraine, Belgium, Canada, Germany, Taiwan, India, Japan, France
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Amsterdam UMC, location VUmc

Unknown

Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients

NSCLC | EGFR-mutation | HER2-expression

Netherlands
Hanmi Pharmaceutical Company Limited

Completed

Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer

Advanced Solid Tumors
Achieve Life Sciences

Completed

TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium

Carcinoma, Transitional Cell | Ureteral Neoplasms | Urethral Neoplasms | Bladder Neoplasms

United States
Theradex

Unknown

Chemotherapy in Treating Patients With Metastatic Kidney Cancer

Kidney Cancer

United States
Enzon Pharmaceuticals, Inc.

Terminated

Phase I Study of PEG-Paclitaxel In Patients With Advanced Solid Tumors & Lymphomas

Neoplasm Metastasis | Neoplasm | Lymphomas
Alyssum Therapeutics
CBCC Global Research

Recruiting

Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors

Solid Tumor

United States
Bayer

Completed

Iloprost Therapy in Patients With Critical Limb Ischemia

Peripheral Arterial Disease

Hungary
Callisto Pharmaceuticals

Terminated

Liposomal Annamycin in Children and Young Adults With Refractory or Relapsed ALL or AML

Acute Lymphocytic Leukemia | Acute Myelogenous Leukemia

United States
Bio-Path Holdings, Inc.

Recruiting

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory

United States
Imunon

Withdrawn

Heat-Activated Target Therapy of Local-Regional Relapse in Breast Cancer Patients (EURO-DIGNITY)

Breast Cancer

Israel, Czechia, Italy
Merck Sharp & Dohme LLC
Princess Margaret Hospital, Canada

Completed

A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian Cancer Recurrent Within Six to Twelve Months After Initial Carboplatin and Paclitaxel Chemotherapy (P03625)

Ovarian Neoplasms
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

Lymphoma | Leukemia | Breast Cancer | Ovarian Cancer | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm

United States
Catholic University, Italy
Cephalon

Unknown

A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging (LITE)

Breast Cancer

Italy
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Breast Cancer

United States
Indiana University

Completed

Endoscopic Ultrasound (EUS)-Guided Ablation of Pancreatic Cysts

Pancreatic Cyst | Pancreatic Intraductal Papillary-Mucinous Neoplasm | Cystadenoma, Mucinous | Papillary Mucinous Cystadenoma, Borderline Malignancy

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Triple Negative Breast Cancer

China
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Paclitaxel, Cisplatin, Gefitinib, and Radiation Therapy Followed by Surgery and Gefitinib in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction That Can Be Removed By Surgery

Esophageal Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute
United States Department of Defense

Terminated

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Ovarian Cancer

United States
Hellenic Oncology Research Group
University Hospital of Crete

Terminated

Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer

Breast Cancer

Greece
Millennium Pharmaceuticals, Inc.

Withdrawn

Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

Ovarian Cancer

Italy, Switzerland
University of Utah
Celgene Corporation

Completed

A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer (VA)

Advanced or Metastatic Solid Tumors | Advanced or Metastatic Breast Cancer

United States
Shanghai Yizhong Pharmaceutical Co., Ltd.

Recruiting

Paclitaxel Polymeric Micelles for Injection Versus TPC on the Treatment of HER2-negative Metastatic Breast Cancer (MBC).

Metastatic Breast Cancer (MBC)

China
Japanese Foundation for Cancer Research
Chugai Pharmaceutical

Active, not recruiting

A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer (AMBITION)

Breast Cancer

Japan
Osaka Medical Center for Cancer and Cardiovascular...

Completed

A Study of Chemoradiotherapy Using Gem Plus Nab-paclitaxel for Pancreatic Cancer

Pancreatic Cancer

Japan
University of Arizona
National Cancer Institute (NCI)

Completed

Alimta® Plus Cisplatin & Paclitaxel Given Intraperitonelly; First Line Tx Stage III Ovarian Cancer

Ovarian Cancer | Fallopian Tube Cancer | Peritoneal Cavity Cancer

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Terminated

Paclitaxel in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Sarcoma

United States, Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Paclitaxel in Treating Older Patients With Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Mary Babb Randolph Cancer Center at West Virginia...

Completed

Paclitaxel in Treating Patients With Early-Stage Bladder Cancer

Bladder Cancer

United States
European Organisation for Research and Treatment...

Completed

Paclitaxel in Treating Patients With Refractory or Recurrent Endometrial Cancer

Endometrial Cancer

Belgium, Austria, United Kingdom, Portugal, Italy, Spain
Theradex

Unknown

Paclitaxel in Treating Patients With Metastatic, Recurrent, or Unresectable Cancer of the Esophagus

Esophageal Cancer

United States
Korean Gynecologic Oncology Group

Unknown

A Safety and Efficacy of CCRT With Paclitaxel as Adjuvant Therapy to Post-Operative Advanced Endometrial Cancer Patients

Endometrial Cancer

Korea, Republic of
Juan LI, MD

Recruiting

Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC

Stage III Non-small Cell Lung Cancer

China
NovoCure Ltd.

Completed

Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)

Ovarian Cancer

United States, Israel, Belgium, Netherlands, Hungary, Germany, Poland, Canada, Austria, Czechia, Italy, Spain, Switzerland
Hoffmann-La Roche

Completed

A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (SAPPHIRE)

Breast Cancer

Australia
Atlantic Health System
Cornerstone Pharmaceuticals

Unknown

A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer | Metastatic Pancreatic Cancer

United States
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer (NAPGAP)

Advanced Pancreatic Cancer

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

SHR-A1811 Versus Investigator's Chemotherapy in Recurrent/Metastatic Breast Cancer Clinical Trial

Breast Cancer

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

PD-1 Antibody Combined Neoadjuvant Chemotherapy for Ovarian Cancer

Ovarian Cancer | Neoadjuvant Chemotherapy | Anti-PD-1 | Neoadjuvant Immunotherapy

China
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Cervical Small Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
Moleculin Biotech, Inc.

Completed

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

Poland
Moleculin Biotech, Inc.

Completed

Study of Liposomal Annamycin for the Treatment of Subjects With Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase Ib/III Clinical Study to Evaluate the Efficacy and Safety of IBI318 in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel in Patients With Small Cell Lung Cancer Who Have Failed First-line or Above Chemotherapies

Small Cell Lung Carcinoma

China
Samsung Medical Center

Completed

Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy

Advanced Gastric Cancer

Korea, Republic of
M.D. Anderson Cancer Center
American Regent, Inc.

Terminated

Study of Weekly LOC-paclitaxel Injection for Melanoma

Melanoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian or Primary Peritoneal Cancer

Ovarian Cancer | Primary Peritoneal Cavity Cancer

United States
Theradex

Unknown

DHA-Paclitaxel in Treating Patients With Metastatic Prostate Cancer

Prostate Cancer

United States

3

Subscribe